May 1, 2025GeoVax Labs, Inc. beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.59. Operator: Good afternoon. And welcome everyone to the GeoVax First Quarter 2025 Corporate ...

(NEPC). The findings enhance the understanding of the treatment of androgen receptor functions in NEPC. Neuroendocrine prostate cancer (NEPC) arises primarily through neuroendocrine ...

Welcome to the Adaptive Biotechnologies first-quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the ...

Q1 2025 Earnings Call Transcript May 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.52, expectations ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced data from preclinical studies of three exatecan-based ...

The American Association for Cancer Research’s annual conference featured updates from several companies on key candidates ...

LAS VEGAS -- Focused ultrasound ablation for prostate cancer proved at least equivalent to radical prostatectomy for ...

The upcoming 12th Annual Clinical Trials in Oncology conference will cover a wide range of topics on clinical research in ...

Nutcracker Therapeutics, Inc., a contract, research, development and manufacturing organization (CRDMO) with a next ?generation RNA precision manufacturing platform, today announced its participation ...